Hit to lead, lead to partnership

Hit to lead, lead to partnership

This is the fourth post in an open science blog series about PERL101 (P101), a small molecule with big hopes. Demystifying drug discovery The default setting of biotech startups and pharma giants alike is stealth mode. At Perlara the default is set to open. As the...
Funding announcement

Funding announcement

This week we announced a $7.4M equity financing. Endpoints News and STAT News covered the announcement and the Twitter angle. Here’s the backstory from the CEO’s vantage point. From the outside, this round appears to be our Series A. But it’s technically our...
Midsummer updates

Midsummer updates

Perlara midsummer 2017 updates—We took a temporary hiatus from blogging starting in March right after my Rare Disease Day post. The reason: fundraising. Raising money is personally all-consuming for the CEO, as I’ll attest in an upcoming post. It’s also a...
World Rare Disease Day 2017

World Rare Disease Day 2017

This post is dedicated to World Rare Disease Day (WRDD) 2017. It was at the WRRD four years earlier when the value proposition for Perlara crystalized in my mind. I went to NIH that frosty last day of February in order to meet with patient advocates and ask them one...
Translate »